You are here

Serotype independent therapeutic vaccine for Streptococcus pneumoniae

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI129218-01
Agency Tracking Number: R43AI129218
Amount: $438,765.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: R
Solicitation Number: PA15-269
Solicitation Year: 2015
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-02-10
Award End Date (Contract End Date): 2019-07-31
Small Business Information
Gaithersburg, MD 20878-1757
United States
DUNS: 601000750
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (240) 454-8940
Business Contact
Phone: (301) 644-3910
Research Institution

In the era of growing antibiotic resistancelife threatening infections with several bacterial pathogens are cause
for major concernApproved vaccines exist only for a handful of bacterial pathogensEven when a vaccine is
available invasive bacterial diseases can occur due to lack of serotype coveragepoor vaccine response among
vaccinated populationsor because many simply don t get vaccinatedThusinnovative concepts are needed to
cope with these challengesThe current proposal is aimed at developing a novel post exposure treatment that is
serotype independent and can be applied to a variety of gram positive bacteriaThe approachtermed Infection
Site Targeted universal Bridging AntigenISTuBAexploits the ability of species specificbut serotypeindependentphage derived bacterial cell wall binding domainsCBDto target anImmunoBridgean antigen
against which most people have antibodiesto the surface of bacteriaThe CBD will redirect the pre existing
immunity against ImmunoBridge towards the new invading pathogen leading to clearance of infectionIn this proposal prototype ISTuBAs will be created for Streptococcus pneumoniaethe leading cause of
community acquired pneumonia as well other life threatening infectionsIn preliminary studies we have
demonstrated that ISTuBAs based on an attenuated staphylococcal enterotoxin B vaccineSTEBVaxas
ImmunoBridge and Spneumoniae specific CBDs can direct an Saureus specific antibody response to mediate
opsonophagocytosis of Spneumoniae strainsBuilding upon these strong preliminary datain Aimwe will test
a wide range of candidate CBDs for binding against a broad panel of pneumococcal serotypes to identify the best
CBDsA short list of broadly reactive CBDs with high affinity will be used to create candidate ISTuBAs in Aimusing not only STEBVax but also diphtheria toxoidCRMand Tetanus toxoid as ImmunoBridgeThe
candidate ISTuBAs will be thoroughly characterized for biochemical and functional properties including
opsonophagocytosis in presence of anti ImmunoBridge antibodiesTwo best ISTuBA candidates will be tested
in mouse intranasal model of Spneumoniae infection in AimUpon successful completion of Phase I we
anticipate a Phase II project that will focus on optimization of the constructsextensive efficacy testing in both
pneumonia and sepsis modelsformulationpharmacokinetics and other IND enabling studies

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government